Galectin director granted 60,000 stock options

Galectin Therapeutics Inc director Henry Brem received a grant of stock options.

Accepted by SEC EDGAR 03/17/2026 - 09:46 AM EDT

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Galectin Therapeutics Inc director Henry Brem received a grant of stock options. The award covers 60,000 stock options, each allowing the purchase of one share of common stock at an exercise price of $3.1600 per share, reported as a direct holding.

The options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. They vest 100% on December 31, 2026 and are scheduled to expire on March 12, 2036. Following this grant, Brem holds 60,000 stock options linked to Galectin common stock.

Insider Trade Summary

Grant/Award: 60,000 shares

Grant/Award 1 txn

Insider Brem Henry

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	60,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 60,000 contracts (Direct)

Footnotes (2)

F1. The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.
F2. The options vest 100% on December 31, 2026.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Henry Brem report in his latest Form 4 for GALT?

Henry Brem reported receiving a grant of stock options in Galectin Therapeutics Inc. The filing shows 60,000 stock options were awarded, giving him the right to buy an equal number of common shares at a fixed exercise price in the future.

How many Galectin Therapeutics (GALT) stock options were granted to Henry Brem?

Henry Brem was granted 60,000 stock options linked to Galectin common stock. Each option corresponds to one underlying share, as disclosed, and all 60,000 options are reported as directly owned after the transaction, according to the Form 4 filing details.

What is the exercise price of Henry Brem’s new GALT stock options?

The exercise price of Henry Brem’s stock options is $3.1600 per share. This means he can purchase Galectin Therapeutics common stock at $3.1600 for each of the 60,000 options, subject to vesting and before the stated expiration date in the filing.

When do Henry Brem’s Galectin Therapeutics stock options vest and expire?

The options vest 100% on December 31, 2026 and expire on March 12, 2036. Brem must wait until full vesting to exercise them, and he must do so before the expiration date specified in the Form 4 and related footnotes.

Were Henry Brem’s GALT stock options granted under a company equity plan?

Yes, the stock options were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan. The Form 4 footnotes specify that this plan is the source of the 60,000-option award reported in the transaction.

Does Henry Brem’s Form 4 show any open-market buying or selling of GALT shares?

No, the Form 4 reflects a grant or award acquisition, not an open-market trade. The transaction code is “A,” indicating a grant of derivative securities, and the summary data show no buy or sell transactions in common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brem Henry

(Last)

(First)

(Middle)

4960 PEACHTREE INDUSTRIAL BLVD

SUITE 240

(Street)

NORCROSS

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock option (right to buy)⁽¹⁾	$3.16	03/12/2026		A		60,000		⁽²⁾	03/12/2036	Common Stock	60,000	$0	60,000	D

Explanation of Responses:

1. The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

2. The options vest 100% on December 31, 2026.

	Jack W. Callicutt, by power of attorney	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR